GenMark Diagnostics, Inc. (NASDAQ:GNMK)‘s stock had its “buy” rating reissued by stock analysts at Cowen and Company in a research note issued to investors on Friday. They currently have a $10.00 price target on the medical equipment provider’s stock. Cowen and Company’s price objective suggests a potential upside of 134.74% from the stock’s previous close.

Several other research firms also recently weighed in on GNMK. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price objective (down from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. BidaskClub downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective (down from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $13.00 price objective on shares of GenMark Diagnostics in a research note on Thursday, August 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.20.

Shares of GenMark Diagnostics (NASDAQ GNMK) traded down $3.04 during mid-day trading on Friday, hitting $4.26. The stock had a trading volume of 7,043,372 shares, compared to its average volume of 359,599.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 113.51%. The firm had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $14.56 million. During the same period in the previous year, the business earned ($0.27) earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. analysts anticipate that GenMark Diagnostics will post -1.06 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “GenMark Diagnostics, Inc. (GNMK) Stock Rating Reaffirmed by Cowen and Company” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/03/genmark-diagnostics-inc-gnmk-stock-rating-reaffirmed-by-cowen-and-company.html.

In other GenMark Diagnostics news, SVP Eric Stier sold 2,750 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $9.60, for a total transaction of $26,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Scott Mendel sold 2,898 shares of the stock in a transaction on Monday, August 21st. The shares were sold at an average price of $9.45, for a total value of $27,386.10. Following the sale, the chief financial officer now owns 138,096 shares in the company, valued at approximately $1,305,007.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,636 shares of company stock worth $522,648. 7.50% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Wrapmanager Inc. acquired a new stake in GenMark Diagnostics during the 3rd quarter valued at $172,000. FDx Advisors Inc. acquired a new stake in GenMark Diagnostics during the 3rd quarter valued at $231,000. Jennison Associates LLC grew its holdings in GenMark Diagnostics by 0.7% during the 3rd quarter. Jennison Associates LLC now owns 3,567,001 shares of the medical equipment provider’s stock valued at $34,350,000 after buying an additional 25,254 shares during the last quarter. OLD National Bancorp IN acquired a new stake in GenMark Diagnostics during the 3rd quarter valued at $217,000. Finally, Northpointe Capital LLC boosted its holdings in shares of GenMark Diagnostics by 24.4% during the third quarter. Northpointe Capital LLC now owns 1,552,740 shares of the medical equipment provider’s stock worth $14,953,000 after purchasing an additional 304,232 shares during the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Analyst Recommendations for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.